Printer Friendly

CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT IN PHASE I TRIAL WITH GENENTECH HIV-1 VACCINE

 WORCESTER, Mass., June 8 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) announced today that its Stimulon(tm) QS-21 adjuvant is being used in a vaccine developed by Genentech, Inc. (NYSE: GNE) against HIV-1 (rsgp120/HIV-1). Inoculations using the vaccine began in late May as part of a Phase I human trial.
 The trial, part of an ongoing agreement between Cambridge Biotech and Genentech, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), and will be conducted by NIAID's AIDS Vaccine Evaluation Group (AVEG).
 In the HIV-1 trial, Stimulon QS-21 will be evaluated for safety and immunogenicity. The trial will enroll 80 healthy (sero-negative), adult volunteers at low risk for HIV-1 infection. These participants will be vaccinated at intervals over a year and subsequently monitored.
 "We believe that this trial is a milestone in the application of vaccine design," said Dr. Charlotte Kensil, Ph.D., Section Manager of Natural Products Chemistry at Cambridge Biotech and inventor of Stimulon QS-21. "While new generation vaccines use only noninfectious parts of viruses or bacteria known to stimulate immunity and are therefore safer, they are potentially weaker. We believe that the new generation vaccine formulations will be enhanced by the inclusion of QS- 21, a component that significantly increases immune responses."
 Dr. Jack Obijeski, Senior Director of Product Development at Genentech, commented: "We're confident that this trial will reveal important data regarding QS-21 and its usefulness in combination with gp120. The study is well designed and should help us move closer to developing a prophylactic vaccine."
 Adjuvants are key components of vaccines that boost their ability to elicit strong responses from the immune system. Like the microprocessor chip in a computer, the adjuvant functions as a power builder within the vaccine, increasing its ability to prevent and treat disease. Cambridge Biotech's Stimulon QS-21 adjuvant holds the promise of being a "universal adjuvant" serving next generation vaccines.
 In 1992, Stimulon completed a Phase I clinical trial of a vaccine against malignant melanoma at Memorial Sloan-Kettering Cancer Center. In that trial, the adjuvant elicited antibody responses at high concentrations in all participants.
 Dr. Patrick J. Leonard, president and CEO of Cambridge Biotech, said, "Adjuvant technology is at the cutting edge in the fight against many of the most widespread health concerns of our time. We believe that QS-21 will help provide more effective, less costly solutions to a wide range of infectious and viral diseases. AIDS is certainly the most serious of the problems being confronted. We are proud to count Genentech among our alliance partners, and we are hopeful that this vaccine trial will provide data beneficial to the prevention of this devastating disease."
 Cambridge Biotech Corporation is a leading diagnostics and therapeutics company involved in infectious diseases. The company is developing vaccines, adjuvants and diagnostics for humans and animals.
 Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant medical needs. The company has headquarters in South San Francisco, California, and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.
 -0- 6/8/93
 /CONTACT: Frederick V. Casselman, vice president of legal affairs & technology licensing, Cambridge Biotech Corporation, 508-797-5777, x507/
 (CBCX GNE)


CO: Cambridge Biotech Corporation; Genentech, Inc. ST: Massachusetts IN: MTC SU:

DD -- NE003 -- 6371 06/08/93 08:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:558
Previous Article:ULTIMAP TODAY ANNOUNCES ELECTION OF NEW SENIOR OFFICERS
Next Article:NATIONWIDE HEALTH SCREENING AND PREVENTION PROGRAM FOR PERIPHERAL ARTERIAL DISEASE IS ANNOUNCED DURING CEREMONIES ON CAPITOL HILL
Topics:


Related Articles
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
CAMBRIDGE BIOTECH CORPORATION AND GENENTECH, INC. AGREE TO VACCINE ALLIANCE
RESULTS OF HUMAN PHASE I TRIAL OF CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT REPORTED
CAMBRIDGE BIOTECH ANNOUNCES POSITIVE IMMUNOSTIMULATIVE RESULTS FOR STIMULON ADJUVANT IN MELANOMA TRIALS AT MEMORIAL SLOAN-KETTERING
CAMBRIDGE BIOTECH ANNOUNCES POSITIVE IMMUNOSTIMULATIVE RESULTS FOR STIMULON ADJUVANT IN MELANOMA TRIALS AT MEMORIAL SLOAN-KETTERING
THERION BIOLOGICS BEGINS PHASE I CLINICAL TRIAL WITH AIDS VACCINE IN COLLABORATION WITH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
WYETH-AYERST BEGINS TESTING LIPOSOMAL FLU VACCINE; THE LIPOSOME COMPANY'S NEW ADJUVANT MAY BOOST PROTECTION
Aquila Announces Initial Results Of Phase II Clinical Trial Of Quilimmune-P(TM) To Prevent Pneumococcal Infections.
Aquila Announces Preliminary Results From Phase I Clinical Trial Of Quilimmune-M(TM) Malaria Vaccine.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters